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Abstract
Background: Patients currently integrate complementary medicine (CM) and allopathic, choosing a combination of
therapies rather than a single therapy in isolation. Understanding integrative healthcare (IHC) extends beyond
evaluation of specific therapies to encompass evaluations of multidisciplinary complex interventions. IHC is defined
as a therapeutic strategy integrating conventional and complementary medical practices and practitioners in a
shared care setting to administer an individualized treatment plan. We sought to review the outcomes of recent
clinical trials, explore the design of the interventions and to discuss the methodological approaches and issues that
arise when investigating a complex mix of interventions in order to guide future research.
Method: Five databases were searched from inception to 30 March 2013. We included randomized and
quasi-experimental clinical trials of IHC. Data elements covering process of care (initial assessment, treatment
planning and review, means for integration) were extracted.
Results: Six thousand two hundred fifty six papers were screened, 5772 were excluded and 484 full text articles
retrieved. Five studies met the inclusion criteria. There are few experimental studies of IHC. Of the five studies
conducted, four were in people with lower back pain. The positive findings of these studies indicate that it is
feasible to conduct a rigorous clinical trial of an integrative intervention involving allopathic and CM treatment.
Further, such interventions may improve patient outcomes.
Conclusions: The trials in our review provide a small yet critical base from which to refine and develop larger studies.
Future studies need to be adequately powered to address efficacy, safety and include data on cost effectiveness.
Systematic review of clinical trials of integrative
healthcare
You think that because you understand “one” that you
must therefore understand “two” because one and one
make two. But you forget that you must also understand
“and”. —Sufi teaching story [1]
Background
Patients are integrating complementary medicine (CM)
and allopathic medicine in a variety of ways depending
on their health status and health beliefs [2, 3]. They fre-
quently use “bundles” of therapies rather than just one
therapy in isolation [4, 5]. Typically the unit of integra-
tion in clinical environments is the patient rather than
the practitioners [6, 7]. Increasingly consumers are
requesting that there be improved communication and
coordination between their allopathic care and CM
providers [8]. In response to this consumer demand in-
tegrative healthcare (IHC), (also referred to as integra-
tive medicine), has emerged over the past two decades
[9, 10]. For healthcare policy makers, care providers,
practitioners and the consumer, we need to know
whether IHC is effective and, if so, what structures and
processes combine to exert the positive outcome. Early
experimental efforts have been made to investigate the
effectiveness and efficacy of this evolving IHC model of
patient care [11–13]. We sought to review the out-
comes of recent clinical trials, explore the structure of
the interventions and also to discuss the methodo-
logical approaches and issues that arise when investi-
gating a complex mix of interventions in order to
guide future research.
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The varied definitions for IHC reflect differing inter-
pretations and implementation [11, 14–16]. There is a
common general underlying philosophy that IHC aims
to treat the whole person (physical, emotional, ener-
getic, spiritual), using the body’s innate ability to heal it-
self with a blend of conventional and complementary
therapies [11, 14]. However, definitions of IHC splinter off
when the structure and process of care are considered. For
example, IHC may refer to the process of patient care where
allopathic and CM clinicians work as a team. The team
may operate in a multi-disciplinary or inter-disciplinary
way. There may be a democratic referral system or the
allopathic physician may be the gatekeeper and the
CM practitioner is adjunct practitioner [17–19]. In
other cases, ‘integrative’ may refer to a clinician who
‘integrates’ both allopathic and CM. Further confusion is
added to the typology of this field by regional variations,
where “integrated” is used in the United Kingdom (UK)
and parts of Europe, in the same way in which “integrative”
is used in the United States (US) and Australia.
The focus of this paper is IHC defined as a patient-
centred, inter-disciplinary approach where there is a com-
bination of conventional medicine with CM with shared
patient assessment, treatment planning, review and/or
shared practice guidelines that are constructed and utilised
during the care process. This therapeutic strategy enables
each practitioner, often in conjunction with the patient, to
contribute their knowledge and expertise towards providing
individualized healthcare plans.
In this emerging field, there are no ‘right’ or ‘wrong’
ways for patients to experience a combination of CM
and allopathic medicine. Some conditions or people may
be better suited to different processes of care. However,
it is important to distinguish clearly between approaches
which are adjunctive or complementary therapy and not
integrative as they are different entities, have different
organisational and resource implications, and likely, dif-
ferent benefits [14, 20]. Adjunctive or complementary is
where a therapy is used in addition to allopathic medi-
cine but not involving any shared assessment, manage-
ment or review in the process of care.
Research methodology to evaluate IHC has tended to
use observational designs, pre and post-test, or descrip-
tive methods, but more recently there has been a move
to the use of experimental design [21, 22]. IHC is a
‘complex intervention’, using experimental design with
a complex intervention is challenging but feasible [23].
By ‘complex intervention’ we mean that there are many
active components, which may combine to provide out-
comes greater than a sum of its individual parts [11,
24]; that may involve complex mechanisms for delivery;
may be difficult to replicate (tailored to individual); and
may be influenced by the environment and social con-
text. As such it is extremely challenging to clearly
articulate mechanisms of action [23, 25]. IHC is often
highly individualized, taking into consideration all as-
pects of a person not only one condition or symptom,
has varied participant responses, with different practi-
tioners in different settings [26, 27]. Determining the
outcomes of a complex intervention requires a combin-
ation of qualitative and quantitative methods [23] and a
consideration of the different experimental designs
available [28]. In addition to measuring outcomes, un-
derstanding the complex intervention may be aided by
including a nested process evaluation or similar.
Process evaluations within trials explore the implemen-
tation, receipt, and setting of an intervention and help
in the interpretation of the outcome results [24].
Hence, our review has three primary objectives:
1. To systematically review the quality and outcomes
of clinical trials of IHC
2. To explore the design of IHC interventions,
including process of care
3. To review research methodology employed in IHC
clinical trials
Methods
Eligible CM therapies were defined according to the
National Institute of Complementary Medicine (NICM)
[29]. NICM has adopted, with revisions, the four
domains of CM articulated by the US National Centre
for Complementary and Integrative Health (NCCIH).
These domains are mind-body medicine, biologically-
based practices, manipulative and body-based practices
and energy medicine [30]. We included any clinical trial
or protocol that was conducted in an IHC setting where
there was a combination of at least one biomedical
practitioner and one CM practitioner; and included an
element of shared care or co-management of the
patient at the stage of initial assessment, treatment
plan development, case management or review. Clin-
ical trials of multidisciplinary care where there was no
element of co-management or patient sharing were
excluded. Similarly, we excluded trials where the CM
treatment was adjunctive and there was no shared
management. Trials in integrative oncology were not
examined in this review as the process of care in
oncology settings differs from primary care settings,
where the lead therapy is allopathic medicine and the
lead clinician is the oncologist. Those conducted in
an in-patient hospital setting were also excluded.
Studies were also excluded which were not transferra-
ble to a Western setting due to the different infra-
structures in non-Western settings (e.g. Chinese
medicine in China).
We searched PubMed (Medline), EMBASE, CINAHL,
Clinical Trials Register and the Cochrane Library from
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inception to 30 March 2013. The following search terms
were used, in various combinations: ‘integrated or integra-
tive medicine’ or ‘healthcare’; ‘multidisciplinary care’;
‘complementary’; ‘alternative’; ‘biomedicine’; ‘conventional’;
‘mainstream’ with ‘medicine’; ‘healthcare’; ‘approach’; ‘ther-
apies’. We also hand searched the citations of relevant
papers. We included clinical trials which were random-
ized, non-randomized or case–control. For the purpose of
this study we also included protocols for clinical trials, as
we were not only focused on outcomes but on the struc-
ture and design of the integrative therapeutic intervention.
Our search terms were [(Integrat* OR interdisciplinary)
and (medicine OR alternat* medicine OR alternat* therap*
OR complementary medicine OR healthcare)]; OR [(allo-
pathic OR conventional OR mainstream OR orthodox OR
biomedicine) AND (alternat* medicine OR alternat* therap*
OR complementary medicine OR intergrat*].
To explore the structure and design of the IHC interven-
tion we applied the structure-process-outcome model [31].
Structure was defined as the environment in which health-
care is provided, the process as the method by which
healthcare is delivered and outcome as the consequence of
the healthcare provided. We were particularly interested in
the process component of this model. We defined process
as the way in which the healthcare is delivered – triage,
diagnosis, treatment plan, and review. Central to this
process are the means for collaboration to foster the “inte-
grative” nature of the intervention. These concepts are ex-
plained below:
1. ‘Triage’ in this context refers to how a patient is
‘allocated’ into an IHC intervention or in a clinical
context to a practitioner for initial assessment. In
clinical practice the gatekeeper for this process may
be the receptionist, the practice nurse, or general
practitioner (GP) or may come from an external
referral.
2. ‘Diagnosis’ refers to initial assessment where baseline
data is collected in a clinical trial or where an IHC
assessment is undertaken in clinical practice.
3. ‘Treatment plan’ refers to how the plan is derived,
who is consulted, how it is agreed, types of
treatments, duration, patient preferences and
arriving at responsibility for the patient’s journey
through the IHC process.
4. ‘Review’ refers to measuring outcomes at set time
points, tracking patient compliance,
5. ‘Means for collaboration’: this may include meetings,
shared charting, electronic medical records (EMR),
corridor conversation, shared education and
training, case conferences.
To review the research methodology, we considered
the Medical Research Council (MRC) guidelines [23] for
evaluating complex interventions and extracted data on
the following:
– Was there a theoretical basis for the intervention
and trial design?
– ave the authors sufficiently described their
intervention and the control group?
– How was the intervention evaluated [32]?
– What were the context and the environment of the
intervention?
– How was implementation of the intervention
assessed?
– What was the rationale for the duration of the
intervention?
Two investigators (SG and JF) independently screened all
identified titles and abstracts. Full text reports were re-
trieved. The final decision for inclusion in the review was
made by two investigators (SG and JF). The quality of the
trials was also reviewed using risk of bias criteria [33]. Each
of the retrieved papers was read in its entirety. A standard-
ized data extraction form was developed to extract data ac-
cording to the set elements. Where data was missing we
attempted to contact authors of the study. Data elements
were then extracted and entered into a matrix according to
the method of Garrard [34]. This approach provided a sys-
tematic and concise organisation of the literature.
Results
A total of 6256 papers were screened. Of these 5772
were excluded based on the title and/or abstract. The
main reasons for exclusion were not relevant (n = 4865),
study of CM usage or attitudes to CM (n = 304), and
conceptual paper or commentary (n = 258). A total of
484 full text articles were retrieved for consideration. A
Preferred Reporting Items for Systematic Reviews and
Meta-Analyses (PRISMA) flow diagram (Fig. 1) shows
details of the study selection. Papers were excluded
where the intervention or clinical practice was a set
multi-disciplinary program or CM was adjunctive not in-
tegrative and there was no shared management (n = 49),
the article was about CM usage (n = 296), the setting
was oncology or inpatient hospital based (n = 149), the
paper was conceptual or commentary (n = 117), exam-
ples of IHC clinical practice (n = 63), or limited to a dis-
cussion of models of IHC (n = 28). Five clinical trials
met the inclusion criteria. We excluded the six clinical
trials that had been included in the previous review [19]
as they did not meet our criteria of integrative manage-
ment or were hospital-based programs.
Study design and setting
Four randomized controlled trials (RCT) and one case
control study met the inclusion criteria of our study.
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Table 1 outlines the study settings and trial designs.
Three studies were conducted in the US, one in the UK
[35] and one in Sweden [36]. There was one three arm
trial comparing, IHC with chiropractic and medical care,
and with conventional medical care alone [37]. Two
were pragmatic trials comparing individualised, integra-
tive care with usual care [36, 38, 39]. The study in the
UK was quasi-experimental design with a wait-list con-
trol group [35].
Settings varied; three were family or primary care medical
centres and the others were conducted within an academic
setting (Northwestern Health Sciences University) or out-
patient hospital setting. In the Sundberg [36] study, an IHC
clinic was set up within a primary care unit in Sweden. Pa-
tients were treated within this clinic or in some cases treat-
ments were provided off-site in the private clinics of
participating providers. Participants were required to pay
five Euros per treatment for the first six treatments, after
which no further payment for CM would be required. In
the Richardson study [35], patients were treated within
the context of a CM outpatient service operating in line
with other National Health Service (NHS) outpatient
provisions in the UK. In all other studies treatments
were free of charge.
Participants
Four of five studies were conducted in people with lower
back pain (LBP), with one study treating neck pain in
addition to LBP [36]. The fifth study was a case control
study that investigated the treatment of referred patients
with over 20 different conditions, although the majority
of the patients treated presented with neck/back pain
[35]. All studies were conducted in adults and enrolled par-
ticipants with diverse backgrounds and co-morbidities. A
total of 751 people were involved in the studies and sample
sizes ranged from 20 participants in a pilot study to 330
adults in the case control study.
Process of care: Triage and diagnosis
Four of the five studies published at least one prelimin-
ary paper outlining the background of the study [40], the
protocol [7, 37], the clinical care pathway [41] or the
model [42] to be used in the clinical trial. In Table 2, the
initial assessment process is outlined. In two studies, the
initial assessment was conducted by a single allopathic
physician [36, 40]. In the other three studies, one study
used an allopathic physician and a CM practitioner to-
gether [38]; another used assessments conducted by a
combination of either a chiropractor, an osteopath or a
medical doctor [37]. The initial assessment was reported
in detail in two of the studies [37, 39].
In the Maiers’ [41] study, an initial baseline profile was
compiled by research study staff. This evaluation included
informed consent, self-report questionnaire, health history,
physical examination and x-rays if indicated. The self-
report questionnaire includes patient perspectives such as
previous experience with treatment, preferences and expec-
tations. This profile was reviewed by the IHC team and a
second visit scheduled and then assessed by the multidis-
ciplinary team for eligibility [39] If eligible the patient then
Records identified through 
database searching 
(n = 4364)
Additional records identified 
through other sources 
(n = 1954)






Full-text articles assessed 
for eligibility 
(n = 484)




Fig. 1 PRISMA flow chart of study selection
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Table 1 Characteristics of IHC Controlled Clinical Trials









201 adults with LBP ≥ 6 weeks (RCT). Integrative, multidisciplinary care:
acupuncture, oriental medicine, cognitive
behavior therapy, exercise, massage,
chiropractic and/or medicine (12 weeks)
Patient Self-Assessment Form (PSAF is a
modified form of MYMOP); Frequency of
symptoms; RMQD modified; Fear avoidance
beliefs questionnaire; Pain Self Efficacy Ques-
tionnaire; EuroQol 5D, improvement pm a 9
point ordinal scale, satisfaction, work loss, and
medication use; also Lumbar dynamic motion
and Torso muscle endurance. Semi-structured
interviews with both patients and providers at
the end of the study.
IHC group statistically significant
improvement in pain reduction, perceived
global improvement and satisfaction with
care.
Vs
Setting: Wolfe Harris Centre for Clinical
Studies, Northwestern Health Sciences
University, Minnesota, USA
Chiropractic care alone. Assessed: wks 12, 52
Eisenberg et
al. 2012 [38]
20 adults with LBP for 3–12 weeks in the
US (RCT, Pilot)
Integrative, individualized care: acupuncture,
chiropractic, massage, occupational therapy,
physical therapy, mind-body techniques,
neurology consultation, nutritional
counselling, orthopaedics consultation, and
psychiatry and rheumatology consultation
and referrals as appropriate, plus usual care
(12 weeks). Treatment provided up to two
times per week, with up to two treatment
modalities per session.
RMQD; Symptom relief using Bothersome
index past 24 h; Pain past 24 h; SF12;
Worry
Week 12 Roland Morris (p < 0.08);
bothersome (p < 0.02); pain (0.005)
Setting: multi-speciality group practice, and
an academic teaching hospital (Outpatients),
Boston, USA
PLUS Usual Care Assessed: wks 2, 5, 12, 26. Preliminary findings: significant difference
in favour of the IHC group on pain
reduction, perceived global improvement
at 12 and 26 weeks.
Vs
Usual care alone including medications,
referral for physical therapy as needed,




120 sub-acute or chronic LBP of at least
4 weeks duration in adults≥ 65 years
(RCT, Pilot).
Collaborative medical, osteopathic and
chiropractic care who comprise a patient-
centred, co-management team
(up to 12 weeks)
Primary outcome self-report LBP on a 11-
point numerical rating scale (NRS); RMQD;
SF36 (Veterans RAND); FABQ; Functional
mobility with Timed Up and Go test;
symptom bothersomeness index past
week; depression and anxiety (Patient
Health Questionnaire-9 for depression;
General Anxiety Disorder −7); Self-report
healthcare utilisation, expenditure and
medication use; Questionnaire to assess
expectations, improvement, satisfaction;
Specific process outcomes: participant and
Protocol only, trial underway. This is a pilot
to assess and refine the collaborative care
model and the sample size has not been
calculated to detect a significant difference















Table 1 Characteristics of IHC Controlled Clinical Trials (Continued)
provider perceptions of the collaborative
care model and the clinical trial design.
Setting: Chiropractic research clinic and
Family Medical Centre, USA
VS
concurrent medical and chiropractic care
provided by an unlinked family medicine
physician and a doctor of chiropractic
Assessed: Baseline, 4, 8 and 12 weeks
(primary endpoint), and every 12 weeks
after up to one year.
VS







80 adults with back/neck pain of at least
2 weeks duration (RCT).
IHC involving an individualized treatment
plan provided by a multidisciplinary IM
team coordinated by a gate keeping GP.
Therapies included seven sessions of a
selection of the following: massage,
manipulative therapy, shiatsu, acupuncture,
qigong (group based) for a period over
10 weeks.
SF36; IM tailored outcomes targeting
self-rated disability, stress and well-being;
Days in pain (0–14); Healthcare utilisation
and medication use. Focus group
discussions exploring participants’
experiences and perceptions of
conventional and integrative care.
Significant improvement in one (vitality)
of the eight domains of the SF-36. Trend
to less medication use in the IHC group.
Underpowered.
Setting: IM clinic operating 5 days per week
at a primary care unit in Sweden 2003-
2006









330 adults with over 20 conditions (quasi-
experimental).
Integrative, multidisciplinary, individualized
care: Acupuncture, Homeopathy, and
Osteopathy for six treatment sessions up to
12 weeks.
SF36 baseline and at completion of
treatment. Patients were asked about their
satisfaction and experience of the service.
Significant improvements in the
intervention group in seven of the SF36
eight domains.
VS
Setting: Complementary Therapy Centre set
up within a hospital, UK
Waitlist















Table 2 Process of care in IHC trials




[39, 41, 44, 89]
Patient completes a baseline evaluation
profile comprising self-report back pain
symptoms, disability, general health status,
fear avoidance, self-efficacy measures and
patient perspectives (previous experiences
with LBP treatments, preferences for care
and expectations of study treatment) as
well as physical exam and objective test
findings.
One or more treatment plans are
developed for the patient at a weekly
meeting. Each treatment plan consists of
one or more modality and consensus must
be reached for the plan to be presented to
the patient. Typically there are three care
plan options consisting of two to three
modalities.
Clinicians attended one full day training
prior to commencing study. Training
included:
Cost effectiveness analysis between
intervention groups using ICER and a cost
utility analysis based on the EuroQoL5D
from a societal perspective.
Before randomisation, the profile is
reviewed by multidisciplinary team during
weekly case review meetings to determine
eligibility. A second baseline evaluation
visit where patients are enrolled and
complete baseline measures. Once
randomized, patients are discussed at
weekly meetings.
Care consultation with patient conducted
by non-clinician case managers where
treatment plans were presented and
patient exerts preference for a plan.
information on each healthcare discipline;
At weekly meetings, clinicians review
patient progress using the PSAF, self-rated
symptoms and activity against benchmarks
of expected improvement. If progress not
satisfactory, a patient’s profile may return
to team meeting for consideration of
changing the treatment plan. Facilitated by
specifically trained non-clinician case
managers.
review of the available clinical evidence on
the effectiveness of each modality when
used to treat LBP;
applying an evidence informed practice
model;
methods for reaching consensus in a team.
Ongoing training as needed throughout
the study.
Site visits by consultant to observe team
dynamics and provide feedback.
Weekly meetings facilitated by
non-clinician.
Shared access to treatment notes.
Eisenberg et
al. [38]
Allopathic doctor and CM clinician evaluate
the patient together.
The two evaluators meet to develop an
individualized treatment plan. Treatment
plan initiated by appropriate clinicians.
Team trained one full day per wk
for 14 weeks prior to study. Co-led
by a professional facilitator, a medical
anthropologist included:
Maximum outcomes with minimum
treatment. Number and frequency of visits
recorded but no cost effectiveness
component included in the study.
At team meetings, cases are presented and
discussed for input from all members and
treatment plan modified by team’s















Table 2 Process of care in IHC trials (Continued)
recommendations. This process was
ongoing.
Experiential education including hands on
diagnosis and treatment by each member
on other team members
Diagnosis and treatment of volunteer
subjects with chronic LBP
The development of a shared treatment





Allopathic doctor served as gatekeeper
with responsibility for overall management
of the patient – only licensed medical
doctors are permitted to fully utilise the
complete range of medical services. The
allopathic doctor had clinical knowledge
and experience of CM.
Consensus case conference with CM
providers to identify appropriate treatment
strategies tailored to the patients’ needs.
Regular team meetings in the lead up to
and during the project Training to work
collaboratively, utilise a consensus case
conference model within primary care,
meeting included:
Patients charged a low fee per treatment and
low maximum treatment cost to obtain all
treatments. No adverse events. The IM model,
on average integrating 7 CT sessions with
conventional primary care over 10 weeks,
resulted in increased QALYs, somewhat
higher cost of healthcare provision but a
reduced cost of using healthcare resources,
including less use of analgesics compared to
conventional primary care. The costs/QALY
ranged between euro 24 000 and 41 00There
was a conservative likelihood of the IC model
being cost-effective at a threshold of EUR
50,000 per quality-adjusted life year gained.
Initial conference followed by regular
consensus case conferences combining
conventional and CM clinical reasoning to
verify and improve clinical management of
patient.
Professional presentations
Aimed for non-hierarchical decision
making.
Educational items on different medical
models
Patients did not participate in the
consensus case conference but via
personal interaction with IM provider.
Case management strategies (approaches
to diagnosis, treatment, prevention and
documentation)
Used a medical record developed
specifically for the trial
Goertz et al.
[37]
Doctor of Chiropractic gathers history,
conducts eligibility examination including
mobility assessment, fracture risk, reviews
scores for depression, anxiety and
substance abuse, and requests any
additional information such as x-rays. All
data recorded on web based form and
reviewed by other physicians and patient
attends second eligibility exam with Doctor
Team of clinicians assigned to case to
follow during 12 weeks.
To prepare for “Shared Care” clinicians
completed a 6-month interprofessional
educational program comprised of ad-
vanced training in LBP both medical and
chiropractic, imaging studies and LBP in
older adults. Interdisciplinary discussions on

















Table 2 Process of care in IHC trials (Continued)
of Osteopathy or medical doctor. Case
review sessions held twice weekly with
DoC and study coordinators present to
agree on inclusion. Patient is then
randomized.
Interprofessional telephone consultation to
discuss patient and establish treatment
plan.
To foster interdisciplinary practice during
the study:
Treatment plan communicated to patient
by next treating practitioner
research record sharing via a secure
electronic Doctor Communications module
specifically constructed and maintained for
the study within a web-based tracking and
reporting system;
Team based case management: interprofessional telephone consultations;
Additional telephone call consultations or
research record exchanges may be
initiated to change treatment plan, refer as
warranted
patient centred treatment planning and
evaluation
half day site visit at partner clinic to






A pilot service run by a consultant physician
and managed by a service manager,
coordinated on a daily basis by a senior staff
nurse who was also qualified in massage.
Patients referred to the service by local GP
and hospitals. The GPs act as gatekeeper and
refers to the service. Referral guidelines were
developed through consensus conference of
27 health professionals. The referral table lists
over 20 conditions suited to one of the three
therapies available and contraindications. GPs
were the gatekeeper for referral to treatment,
and used the referral table for guidance.
Patient preference unclear.
Unclear. Staff meetings regularly held and
audits conducted but not clear if these
discussions altered the patient treatment
plan.
The initial Delphi process involved a half
day discussion of conditions, therapies and
the indications of each for 26 health
professionals.
No
Shared bespoke computer system for patient
demographic and clinical information.
Practitioners discussed cases in staff
meetings which were attended by the
medical director, clinic nurse and other
practitioners. Local GPs were involved in
case presentations where possible.















completed a second baseline visit, was enrolled and ran-
domized to a treatment group.
The Goertz [37] study similarly used research study staff
to conduct an initial baseline evaluation to gather back pain
and chiropractic treatment history, beliefs about chiroprac-
tic, health assessments and a treatment expectations ques-
tionnaire. Once eligibility of the patient was confirmed by
all physicians, a second baseline visit conducted by a
medical or osteopathic physician with a focus on age-
related concerns and the participant is then randomised to
conventional care, dual care or shared care.
In the Sundberg [36] study, after an initial consultation
with a GP at the primary care unit, a conventional treat-
ment plan was developed for every participant. The re-
search team randomised participants to receive either
integrative care or continue with conventional care only.
In the Richardson [35] quasi-experimental study, referrals
were accepted to the study from general practitioners (GPs)
and hospital doctors and patients. In the Eisenberg [38]
study, participants were initially assessed by both a medical
doctor and a CAM clinician.
Process of care: treatment plan
Treatment plan refers to how the plan is derived, who is
consulted, how it is agreed, types of treatments, dur-
ation, patient preferences and arriving at responsibility
for the patient’s journey through the IHC process.
Table 2 provides some detail on how the treatment plans
were derived. Four of the studies used a team approach
to developing one or more treatment plans for each pa-
tient [36–39]. In the team approach, typically non-
hierarchical, consensus based decision making was sought.
None of the case conferences or team meetings to develop
treatment plans involved patient participation.
Patient preferences were considered in two studies. In
one of these studies, the outcome of the team approach
was typically three treatment plan options that were
then presented to the patient by a non-clinician case
manager. The patient was then able to express their
treatment plan preferences [39]. In the other study, a
treatment plan was communicated to the participant
and participant feedback was incorporated into the man-
agement plan [37].
Oversight for the patient’s journey in the trial was not al-
ways clearly documented. In one study it was clearly the
general practitioner (GP) [36], as only medical doctors in
Sweden are able to access the full range of medical services.
In the UK study, a nurse coordinated the patient’s journey
through the study [35].
The type of therapies and combinations were compre-
hensively documented in two of the three fully reported
studies [41, 42]. In the Maier’s study, manual therapy,
exercise and education were the most commonly recom-
mended and selected modality combination followed by
a combination of exercise therapy, education and orien-
tal medicine. An average of 3–4 (3.4) treatment plans
were offered to each of the 101 participants, with an
average of three modalities per plan. Sundberg et al. doc-
umented that patients received around seven treatments,
averaging two different modalities over 10 weeks along
with one session of a self-help activity – qigong. Swedish
massage was the most commonly combined modality.
All study interventions involved one to two treatment
sessions per week with administration of up to two treat-
ment modalities per session. The interventions included
combinations of different practitioners and therapies that
were deemed appropriate to the condition being treated.
The four studies on LBP typically utilized differing
combinations of acupuncture, osteopathy, chiropractic,
massage, mind body techniques and/or exercise. The
case control study used acupuncture, homeopathy and
osteopathy as therapies.
The study comparator was usual care in three studies
[36–38]. The case control study used a waitlist for
comparison, whilst another study compared the IHC
intervention to chiropractic treatment alone [39].
The length of the intervention was 10–12 weeks for
all five studies and none of the studies documented
any data collection of co-morbidities or treatments for
co-morbidities. Only one study provided a rationale for
the length of the intervention, hypothesizing that a
12 week intervention period was typical in treating the
study population [41]. One study had a follow up at
16 weeks [42] and another study had a follow-up
period of 52 weeks [37].
Process of care: Review
All studies had a review process built into the interven-
tion, in some cases a formal process was in place for re-
view and in others cases were only discussed at weekly
staff meetings and informally between practitioners [40].
Re-evaluations were common and of the 101 treatment
plans, 38 were re-evaluated during the course of the
study. The main reasons for re-evaluation were due to lack
of improvement as perceived by the provider, patient or
both. Maiers et al. used a modified Measure Yourself
Medical Outcome Profile (MYMOP) to assess and
modify treatment during the intervention period. This
study also used benchmarks for improvement in the
condition and the case was returned to the team if
benchmarks weren’t met [41].
Process of care: Means for integration and collaboration
Educational sessions or training of therapists and practi-
tioners was conducted in all of the studies prior to com-
mencement [35, 37, 38, 41, 42]. This ranged from a half
day workshop [40] to a six month course in inter-
professional education [37]. In another study, the team
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met weekly for one full day for 14 weeks to undergo
training [38].
Training typically comprised knowledge sharing of the
different modalities to be used in the study, often involving
presentations by each of the practitioners and in some cases
hands on experiential sessions. Evidence for modalities was
also reviewed in these sessions. Four studies referred to
sharing patient medical records and treatment notes. In
some cases specific computer modules or systems had been
constructed specifically for the study.
Team meetings, either face-to-face or via phone, were
also seen as a regular part of the integrative approach. It
was implied in four of the studies that the treatment
plan may be altered as a result of these meetings but this
process was only clearly detailed in two of the studies
[38, 39]. In one study, patient progress was reviewed
using outcome measures being assessed against bench-
marks and if progress was not satisfactory the treatment
plan was modifies.
Four of the studies [36, 37, 39, 40] referred to using an
existing evidence base to guide treatment. Evidence for
effectiveness was typically tempered with clinical experi-
ence and patient presentation. In some cases, the evi-
dence directed the modalities that were selected for
inclusion [37, 39] or guided the referral process [40]. A
care pathway was designed for one study. This provided
a structured process for clinicians to follow including
points along the way to flag treatment review.
Outcome measures and results
Only one of the studies was powered to seek efficacy out-
comes [39] and three trials were pilot studies [36–38]. The
objective of the case control study was to establish the
feasibility of an IHC service as opposed to determining the
efficacy of the service.
The results of the adequately powered study showed
that IHC in people with LBP resulted in statistically sig-
nificant improvements in pain reduction, perceived glo-
bal improvement and satisfaction with care compared to
those patients receiving chiropractic care alone [43, 44].
Quality of life was rated as significantly better in the IHC
group compared to the chiropractic group at 52 weeks. The
feasibility and pilot studies all reported favourable trends
towards the IHC group.
Condition specific outcome measures such as a pain scale
or validated disability questionnaire such as the Roland
Morris Disability Questionnaire (RMQD) were used in four
of the five studies [36–39].
All but one study also used a standardized quality of life
instrument. Only one study [41] used a patient generated
measure, a modified MYMOP [45]. Generalizable cellular
or molecular markers such as inflammation markers were
not collected in any study.
Practitioner and/or patient expectations and percep-
tions of the integrative care approach were reviewed
through semi-structured interviews in four of the stud-
ies [35, 37, 39, 42]. Patients found the holistic approach
of integrative care to be empowering, facilitating self-
help in contrast to the conventional managements
which was disease focused and reductionist, but were
concerned about the challenges of treatment costs [46].
Two other studies are yet to fully publish their qualita-
tive results. The Goertz [37] study has conducted semi-
structured interview to ascertain participant’s perceptions
of back pain improvement, clinical trial experience, expec-
tations, treatment effects, and interprofessional collabor-
ation amongst the treating clinicians. Clinician expectations
of care were also recorded along with their thoughts on ex-
pected improvement of overall quality of life and health sta-
tus and their rationale for the treatment provided.
Cost effectiveness
Crude cost data was collected in one study only [36].
Extra costs of treatment were calculated at 365€. In this
study there was a trend to decreased prescription and
non-prescription medications. The cost of the treatment
only was collected in one other study but has not been
reported [39].
Safety
One minor adverse event was reported out of 170 IHC
interventions provided in one study [38].
Quality of trials
Four of the five studies were randomized controlled tri-
als. Table 3 provides a brief assessment of the risk of bias
of the studies. All trials used appropriate methods of
randomization (computer generated) and reported
allocation concealment. Blinding of care provider and
participants is not possible in an IHC intervention,
although in some cases it is possible to blind the out-
come assessment. Only one trial reported blinding of
outcome assessors where questionnaires were adminis-
tered by research staff not involved in clinical care. The
risk of bias of the RCTs is low if the difficulty of blinding
Table 3 Methodological quality: Risk of bias
Westrom Goetz Eisenberg Sundberg
Random sequence generation Low Low Low Low
Concealment of allocation Low Low Low Low
Blinding of care provider High High High High
Blinding of participants High High High High
Blinding of outcome
assessment
High High High Partial
Incomplete outcome data n/a n/a Low Low
Selective reporting n/a n/a Low Low
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is considered. Blinding of participants and care providers
in a trial where treatment is individualised is not pos-
sible. However, outcome assessment may have been
blinded, one study achieved partial blinding of outcome
assessment [46].
The case controlled study had no randomization [35].
Patients were treated on a first come, first serve basis
and urgent cases were given priority. To address the bias
inherent in such a design the authors followed a quasi-
experimental approach for non-equivalent groups with-
out controlled selection. Sensitivity analysis was con-
ducted on the urgent referrals, and the poor response in
the waitlist group. This waitlist control study has limita-
tions due to expectation bias, and selection bias. There
are also limitations due to the complexity of the inter-
vention and evaluation of the effect applies to the whole
treatment and not to the individual components.
Review of the research methodology
All studies provided an adequate rationale for the inter-
vention and trial design [36–40]. The Richardson [40]
quasi-experimental study was based on a pragmatic ap-
proach and used the convenience of a ready-made wait-
ing list. The rationale for all of the studies was primarily
2-fold: patients are currently integrating various CM;
and the value of this integration remains largely un-
known in terms of outcomes and cost effectiveness.
Table 1 provides a summary of the interventions and
comparators used in the studies. The therapies available
and the comparators are adequately described but the
dosage is not always apparent. In only two of the studies
have the authors sufficiently described the number of
modalities and frequency of sessions of the intervention
on average for the participants [36, 41].
Outcome measures detailed in Table 1 show all studies
sought to evaluate the interventions using a quantitative
measure for quality of life such as SF36 and a symptom
specific tool. All but one study [38] used interviews to ex-
plore participant perceptions of the IHC model and two
studies also included interviews with providers [37, 43].
The implementation of the intervention was assessed
through provider interviews in two of the studies. No other
process evaluation methodology was reported.
The rationale for the duration of the intervention was not
always apparent in the reporting of the studies. One study
provided the following rationale: ‘a 12 week intervention
period was perceived by study clinicians and investigators
to be typical when treating this population’ [41].
Discussion
The small number of IHC trials found in this review was
disproportionate to the amount of literature identified. This
supports the findings of Coulter et al. [20] which con-
cluded that research is still focused on conceptualizing
and practicing IHC not on efficacy [9]. The paucity of
trials also likely reflects the difficulty in undertaking
research on complex interventions such as IHC. How-
ever, there is a need for research that evaluates this in-
tegration, reflects clinical practice and provides an
understanding of efficacy [4, 47]. Reviews or summaries
of this evolving field are sparse and few have focused specif-
ically on clinical trials [19, 48]. It is perhaps timely that we
examine the reporting, structure and outcomes of recent
trials within the context of emerging frameworks for
researching complex interventions so as to guide future
work in this field.
The theoretical rationale reported for undertaking a
clinical trial of an IHC intervention was manifold.
Firstly, in ‘real life’, patients frequently don’t restrict their
CM use to one therapy and often seek to use a combin-
ation [38]. Patients are usually the point at which integra-
tion occurs - ferrying results, treatment plans and x-rays
between providers. It is argued that the most appropriate
point of integration is the provider through IHC [49]. Sec-
ondly, there has been much discussion about conceptual
IHC models but little testing to examine how IHC may be
implemented, at what cost and effectiveness [42]. Thirdly,
the combined effect or synergy of multiple interventions is
hypothesised as likely to be greater than that which can be
achieved by a single modality, particularly for chronic con-
ditions [41]. Provision of an individualised multidisciplinary
intervention provides patients with greater choice, and fa-
cilitates patient participation in the decision-which is asso-
ciated with better health outcomes and satisfaction [50, 51].
Not all health conditions or diseases are suited to an IHC
intervention. In the trials examined in this paper, lower
back pain was the condition selected for four or five trials.
It is likely that this was selected for a number of reasons.
Lower back pain is a prevalent condition which has a high
community and economic cost [52]. Musculoskeletal con-
ditions are one of the most common conditions for which
people consult a CM practitioner utilizing both conven-
tional and CM treatments alongside one another [53, 54].
There was a clear intent within the studies to include mo-
dalities for which a positive evidence base was available. A
recent systematic review and meta-analysis of the efficacy,
cost-effectiveness and safety of selected CMs for neck and
LBP found that CM treatments such as acupuncture, mas-
sage, spinal manipulation and mobilization, were more ef-
fective at reducing pain in the short term than no
treatment, placebo, physical therapy or usual care [52]. Tri-
als typically examined single CM modalities in isolation,
and multidisciplinary approaches rarely included CM ther-
apies. Other types of conditions where IHC interventions
might be useful are likely to be those where CM use is
high, such as the for the treatment of health problems
where there is unmet need and conventional care has not
been able to help; that have an unpredictable course and
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prognosis; and that are associated with substantial pain,
discomfort, or side effects from prescription drug medi-
cine [4, 55]. In a recent paper, IHC leaders nominated
headache, back pain, arthritis and diseases across the meta-
bolic spectrum as areas where the body of CM evidence
was strong and suited an IHC trial [56]. In another study of
general practice, conditions such as musculoskeletal prob-
lems, depression, eczema, chronic pain, and irritable bowel
syndrome were suggested [57].
To understand the IHC interventions – what works
and what doesn’t – we need as much transparency as
possible. In the studies we reviewed development plans
or protocols documented a consistent structure, process
and functional intent around the variable components of
IHC intervention. The completed trials in the review
provided several papers reporting the results of various
aspects of the intervention. In the majority of the studies
this was sufficient detailed to enable the replication of
elements of the design, although a clear parallel evalu-
ation of the process would be of benefit. Only one study
in our review included a nested ‘process evaluation’[37].
Process evaluations within trials explore the implemen-
tation, receipt, and setting of an intervention and help in
the interpretation of the outcome [58]. A process evalu-
ation embedded within future trials may assist in docu-
menting the time taken to construct a patient profile;
the skills needed to collect the information for the pa-
tient profile; the time needed to devise a treatment plan,
present the plan and reach consensus; help to distin-
guish between essential and non-essential components
of the intervention; investigate contextual factors that
affect an intervention; patient responsiveness; practi-
tioner delivery; and monitor dose [23, 59, 60].
Equally useful to understanding the IHC interventions
is to know what ‘guides’ the treatment planning and
management process beyond the integrative care and
management. Table 4 includes a set of ‘guiding princi-
ples’ articulated by Maiers et al.[61]. These principles
serve to clearly delineate the intent or function of the
intervention, and the approach the team should aim to
take. Of these five principles, all studies were guided by
Principles 4, 5 and 6. It was less clear the extent to
which studies were guided by the other three principles.
The basic approach to the provision of care in each of
the studies was guided by Principle 4: using evidence in-
formed interventions and translate existing complemen-
tary and integrative therapies into clinical practice
bringing together practitioner expertise, patient presen-
tation and preference to form the treatment plan [62]. In
some studies, the organisational process of constructing
a treatment plan was documented and this is useful for
future replication. Some of the trials then documented
the frequency and types of treatments patients received
although the details and rationale of the actual treat-
ments are not provided. Journal article length makes this
level of reporting unfeasible. Understanding frequency
and intensity of the individualised treatments may be
graphically depicted in ways suggested by Perera [63].
This may provide an indication of ‘dose’ per individual.
The use of an inadequate dose may be safe and less re-
source intensive but ineffective.
IHC practitioners in all studies were provided with
education and training of variable intent and intensity.
The provision of education and training prior to study
commencement demonstrated an understanding of the
complexity of bringing different professional health dis-
ciplines together [64]. Opportunities for dialogue be-
tween different practitioners and group development
build mutual understanding which is considered import-
ant for success of IHC [65, 66]. Future studies should
consider the informal and formal means for collabor-
ation and team building not only at study commence-
ment but throughout the study. It is likely established
IHC teams would operate in a more timely and cost
effective fashion. Increased team cohesiveness may
lead to improved safety, sharing resources, less oppor-
tunity for negative treatment interactions, reduced
treatment cycles, reduced primary care visits and cost
effectiveness [42].
The studies in our review used disease specific out-
come measures combined with a quality of life measure
and/or a patient reported measure such as MYMOP.
While disease specific measures are important, so too
are outcome measures on IHC interventions that cover
physical, spiritual, psychological and social domains
which go beyond measuring disease specific biomedical
outcomes [67, 68]. Combinations of qualitative and
quantitative measures are best placed to provide com-
prehensive outcome data. Philosophically, IHC and CM
practices are not typically based on a mechanistic cause-
effect relationship with a specific intervention for a spe-
cific symptom. Rather the approach is to bring the whole
person back into ‘balance’ [69]. One study in our review
reported qualitative outcomes relating to changes in
self-concept and empowerment, and benefits arising
Table 4 Guiding principles for an IHC intervention1
Minimal intervention approach to treatment to prevent fear
& castrophizing
Goal of treatment to decrease the patients’ dependency on the health
care system
Limits on treatment should not be arbitrarily applied to care
An evidence informed practice model based on patient presentation,
clinical experience and research evidence
Each individual is unique and treatment should be modified accordingly
Integrative multidisciplinary approach to management
Table modified from Maiers [61]
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from treatment that was ‘whole-person’ focused [46].
This supports other studies that indicate that IHC is
associated with improved health related quality of life
in diverse populations with substantial co-morbidity
[70]. Including measures that capture these outcomes
is particularly relevant if the cost effectiveness of IHC
through its capacity to reduce co-morbidities alongside
disease specific symptoms and improve total well-
being is to be captured [56, 60, 69, 71].
Measuring outcomes and designing IHC interventions
is further complicated by understanding that causality
lies for the effectiveness of an IHC intervention lies not
just with the treatment component but by enhancing the
healing capacity of the patient (salutogenesis) through
the social context and healing environment [72]. The pa-
tient focused, IHC team based approach is thought to
enhance this process as team members contribute
unique perspectives, skills and experience to patient care
[73, 74]. Bell argues that the whole therapeutic strategy
of IHC needs to be evaluated: including the patient-
provider relationship, multiple conventional and CAM
treatments, and the philosophical context of care as the
intervention [69]. Only one of the studies in our review
included measures to attempt to evaluate this process
[75]. Future clinical trials of IHC interventions should
include qualitative elements that seek to understand the
ways in which this process may be fostered to maximise
the specific and nonspecific healing effect of an IHC
intervention.
The strengths of an IHC intervention to provide
good external validity need to be considered against
the inherent limitations of undertaking the evaluation
of a complex intervention using an experimental de-
sign (see Table 5). Defining and articulating the “black
box” of an IHC intervention is important for internal
validity, generalizability and replicability [59]. The dif-
ficulty in doing so within this type of trial design is one
of the key limitations of a complex intervention. The
individualised nature of IHC makes it difficult to know
which component of the intervention is exerting the main
effect - the combination of the therapies, the extra
attention, the patient-practitioner relationship or something
else not considered.
For the purposes of research, IHC is a therapeutic
strategy not a single drug intervention. Team-based,
patient-centred, integrative approaches to care present a
challenge to designing rigorous studies, given IHC is
typically used to provide many simultaneous treatments
for multiple health concerns [68]. Many efforts have
been made to propose frameworks for researching
complex healthcare such as IHC [28, 59, 60, 69] calling
on program theory [73], whole system theory [69, 72],
utilising the Medical Research Council (MRC) frame-
work or employing implementation, process or fidelity
evaluation [59]. Research methodology for evaluating
IHC probably best involves a combination of under-
standing the philosophical underpinnings of IHC
through whole system theory and examining it within
the MRC framework. Whole systems can be defined as
“approaches to healthcare in which practitioners apply
bodies of knowledge and associated practices in order
to maximize the patients’ capacity to achieve mental
and physical balance and restore their own health,
using individualised, non-reductionist approaches to
diagnosis and treatment”[76]. In the case of IHC, it is
the individualised integrative therapeutic strategy that
is the whole system intervention.
The MRC framework follows a typical drug develop-
ment pathway but provides guidance for identifying con-
founders, modelling to predict how components may
interact and identifying the constant and variable com-
ponents of the intervention. Within the MRC framework
a nested “process evaluation” within the study would
provide insight on the constant and variable components
of the intervention. A process evaluation would investi-
gate contextual factors such as setting, team compos-
ition and facilitation, and examine patient-provider
expectations and relationships [24]. A process evaluation
may follow some of the dimensions identified in pro-
gram implementation theory: fidelity, quality of delivery,
participant responsiveness, and program adaptation [77]
Each of these dimensions has been demonstrated to
Table 5 Strengths and weakness of IHC intervention studies
Strengths Challenges/Limitations
Individualised, tailored Active components are obscured
Aims to heal the whole person Difficult to replicate
Suits chronic conditions Poor internal validity
Good external validity Not readily transferrable to other sites as dependent on availability of modalities,
certification of providers, cost
Potential to reduce health costs May require a long trial period with follow up to establish efficacy
and cost effectiveness
Non-specific benefits due to increased attention,
health literacy and education
Non-specific benefits may be practitioner dependent.
Grant et al. BMC Health Services Research  (2015) 15:322 Page 14 of 18
influence outcomes. Strategies may include interviews,
focus groups, and observations alongside document re-
views of clinical files and correspondence. An additional
complexity is that, not unlike conventional interventions
for chronic and complex conditions, research needs to
be conducted over the longer term to truly capture out-
comes. Jonas et al. [72] document an evaluation model
for integrative care specifically for cancer but equally ap-
plicable to understanding and evaluating IHC in primary
care . The model is designed to collect data on well-
being, behavior, clinical outcomes, bio-measures, costs
and the course of treatment and compare IHC with
standard healthcare practices.
A further challenge in IHC research is the preference
of researchers and funders typically prefer investigations
that are linear, showing a clear cause and effect, with few
confounders and cost effectiveness can clearly be deter-
mined [4] . In the US Institute of Medicine examination
of contemporary approaches to CM research acknow-
ledge the limitations of researchers trained in Western
cultures, where complex “systems” with multiple levels
of relationships and multiple factors which are inter-
active and iterative and do not fit into this preferred type
of research [4]. The typical efficacy focused RCT pre-
scribes to the ‘average’ patient and is ‘fundamentally’ at
odds with CM orientation to the ‘individual’ patient .
The number of patients using CM continues to grow, as
does the number of patients that desire a general practi-
tioner who communicates about, and refers to, CM
practitioners. Patients are seeking care that is tailored to
their individual needs and where CM and conventional
medicine collaborate [78–81] with availability of these
treatment options in one location being cited as desir-
able [78]. These considerations aside, patients are
already integrating conventional and CM therapies on
their own due to a desire to access the best that both
healthcare paradigms have to offer [5]. Investigations on
the efficacy, safety and cost effectiveness of an IHC
model of care are warranted to guide health policy
makers and consumers in decision-making and there are
sufficient research and statistical methods available that
enable such investigation.
Proposed RCT designs for complex interventions in-
clude pragmatic trials, factorial design, preference trials
and randomised consent designs, N-of-1 designs [28].
These trial designs may be used to address the prefer-
ences of patients, which are often strong in CM users,
for an integrative approach [82]. In considering compar-
ators and research design, there is a broad consensus
that the evaluation of IHC and CM be conducted where
possible within a comparative effectiveness framework
[28, 83, 84]. The Institute of Medicine defines CER as “the
generation and synthesis of evidence that compares the
benefits and harms of alternative methods to prevent,
diagnose, treat, and monitor a clinical condition or to im-
prove the delivery of care [85]. In selecting comparators for
an experimental design, IHC lends itself with some ease to
comparative effectiveness studies.
The cost effectiveness data collected in the studies in
our review was comprehensive in only one study. Cost
effectiveness analysis for IHC interventions should in-
clude sick leave, medication use, return-to-work and
other cost-related data alongside cost of treatment
course, and compliance. Sundberg et al. [42] recommend
future studies include collection of cost through using
cost diaries, measuring health care visits, sick leave.
From the reviewed studies, it is difficult to determine
the type and level of resources required to conduct IHC
patient assessment and treatment planning. Patient as-
sessment and enrolment in the trials were typically
undertaken by one or two therapists this may increase
cost. Likewise means for collaboration such as meetings
are costly. Any additional duties typically come at a dir-
ect financial cost to fee-for-service practitioners or need
to be compensated for within the IHC model. Con-
versely it is thought that within the integrative whole
person approach there is considerable potential for cost-
effectiveness [56]. Some preliminary data shows that
various CM interventions may be cost effective [86].
Consumers and policy makers need to know if IHC
models are cost effective for effective decision-making.
This review provides an opportunity to consider
methodological challenges that arise in undertaking a
trial of a multidisciplinary, complex intervention. To
enable an understanding of how an individualised
intervention is developed the structure and the process
utilised needs to be transparent. With single interven-
tions, internal validity is maximised by having a stand-
ard dose delivered in the same way at each trial site.
Complex interventions can retain some internal valid-
ity by standardising the process, guiding principles,
and structure of the intervention while allowing the
‘form’ to be adapted [87].
A limitation of our review is that we may have omitted
some studies. Our review is also limited by the inclusion
criteria we selected. Our review supports the findings of
Coulter et al., that the lack of a clear definition and tax-
onomy for integrative health care makes reviewing this
field challenging [19].
Conclusions
The trials in our review provide a small yet critical base
from which to draw upon, refine and develop larger
studies. We recommend pragmatic controlled trials that
document the structure of the IHC environment, the
process of care and measure outcomes beyond those re-
ported in mechanistic efficacy based trials similar to the
efforts being undertaken in the Integrative Medicine
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PrimAry Care Trial (IMPACT) [59]. Complex interven-
tions have inherent limitations not the least of being low
internal validity. To strengthen the quality of the trials,
trials should have built in process evaluations and clear
guiding principles that provide structure beyond the in-
dividualized treatment components. Such trials will pro-
vide evidence of efficacy, safety and identify challenges
and opportunities of this healthcare strategy. The trials
will complement the large scale observational studies of
IHC interventions such as that conducted on Chronic
Pain by the Bravewell Integrative Medicine Research
Network (BRAVENET) collaborators [88]. An evidence
base on IHC is needed to inform patients and healthcare
providers and policy makers. Future research in the IHC
field would do well to build on the recommendations
from the existing body of experimental design. In
chronic illnesses where there is enormous burden there
is considerable merit in investigating an IHC approach
to see if it is able to reduce the health costs.
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